Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
Proteus mirabilis, a common cause of urinary tract infection (UTI), expresses several types of fimbria including mannose-resistant/Proteus-like fimbriae (MRP), uroepithelial cell adhesin (UCA), renamed non-agglutinating fimbriae (NAF) by some authors, and P. mirabilis fimbriae (PMF), which are potentially involved in adhesion to the uroepithelium. In this study, we immunised different groups of mice with recombinant structural subunits of these fimbriae (MrpA, UcaA and PmfA) using two mucosal routes (nasal and transurethral) and we transurethrally challenged the animals with a P. mirabilis uropathogenic isolate. Induction of specific serum and urine IgG and IgA was measured to assess the potential role of the humoral immune response in protection against experimental ascending P. mirabilis UTI. Intranasally MrpA- and UcaA-immunised mice were protected against P. mirabilis ascending UTI, since recovery of bacteria from kidneys and bladders was significantly lower than in PBS-treated mice, and both fimbrial subunits significantly induced specific serum and urine antibodies. Only MrpA and PmfA transurethrally immunised animals were protected only at the kidney level, and in this case only MrpA-immunised mice exhibited significant serum IgG induction. Correlation analysis did not show a significant relationship between serum and urine specific antibody response and protection observed against infection. Our results suggest that an immunisation strategy based on structural fimbrial proteins may be useful to prevent P. mirabilis UTI. Further studies are being carried out to characterise the immune and inflammatory response induced by P. mirabilis recombinant fimbrial subunits.
Scavone
Paola
P
Laboratorio de Microbiología, Instituto de Investigaciones Biológicas Clemente Estable, Avda. Italia 3318, Montevideo CP11600, Uruguay.
Sosa
Vanessa
V
Pellegrino
Rafael
R
Galvalisi
Umberto
U
Zunino
Pablo
P
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000652:urine; D001426:Bacterial Proteins / Q000008:administration & dosage* / Q000276:immunology; D005260:Female; D036781:Fimbriae Proteins / Q000008:administration & dosage / Q000276:immunology; D010861:Fimbriae, Bacterial / Q000276:immunology*; D007114:Immunization; D051379:Mice; D009092:Mucous Membrane / Q000276:immunology*; D011512:Proteus Infections / Q000382:microbiology / Q000517:prevention & control; D011513:Proteus mirabilis / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000276:immunology; D014521:Urethra; D014552:Urinary Tract Infections / Q000382:microbiology / Q000517:prevention & control*
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D011994:Recombinant Proteins; C093283:UcaA protein, Proteus mirabilis; C079120:mrpA protein, Proteus mirabilis; D036781:Fimbriae Proteins